

Hypothyreose

Hypothyroidie

Literatur / Références

1. <http://www.ic.nhs.uk/pubs/prescostanalysis2011>.
2. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. *Arch Intern Med* 2000; 160, 526–534.
3. Hollowell JG, Staehling NW, Flanders WD et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab* 2002; 87, 489–499.
4. Szabolcs I, Podoba J, Feldkamp J et al. Comparative screening for thyroid disorders in old age in areas of iodine deficiency, long-term iodine prophylaxis and abundant iodine intake. *Clin Endocrinol (Oxf)* 1997; 47, 87–92.
5. Tunbridge WM, Evered DC, Hall R et al. The spectrum of thyroid disease in a community: the Whickham survey. *Clin Endocrinol (Oxf)* 1977; 7, 481–493.
6. Vanderpump MP, Tunbridge WM, French JM et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. *Clin Endocrinol (Oxf)* 1995; 43, 55–68.
7. Andersen S, Bruun NH, Pedersen KM, Laurberg P. Biologic variation is important for interpretation of thyroid function tests. *Thyroid* 2003; 13, 1069–1078.
8. Leow MK. A mathematical model of pituitary--thyroid interaction to provide an insight into the nature of the thyrotropin--thyroid hormone relationship. *J Theor Biol* 2007; 248, 275–287.
9. van Deventer HE, Mendu DR, Remaley AT, Soldin SJ. Inverse log-linear relationship between thyroid-stimulating hormone and free thyroxine measured by direct analog immunoassay and tandem mass spectrometry. *Clin Chem* 2011; 57, 122–127.
10. Behrends J, Prank K, Dogu E, Brabant G. Central nervous system control of thyrotropin secretion during sleep and wakefulness. *Horm Res* 1998; 49, 173–177.
11. Brabant G, Ranft U, Ocran K, Hesch RD, von zur Muhlen A. Thyrotropin--an episodically secreted hormone. *Acta Endocrinol (Copenh)* 1986; 112, 315–322.
12. Roelfsema F, Pereira AM, Veldhuis JD et al. Thyrotropin secretion profiles are not different in men and women. *J Clin Endocrinol Metab* 2009; 94, 3964–3967.
13. Warner MH, Beckett GJ. Mechanisms behind the non-thyroidal illness syndrome: an update. *J Endocrinol* 2010; 205, 1–13.
14. Hamblin PS, Dyer SA, Mohr VS et al. Relationship between thyrotropin and thyroxine changes during recovery from severe hypothyroxinemia of critical illness. *J Clin Endocrinol Metab* 1986; 62, 717–722.
15. Garber JR, Cobin RH, Gharib H et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. *Thyroid* 2012; 22, 1200–1235.
16. Mariotti S, Caturegli P, Piccolo P, Barbesino G, Pinchera A. Antithyroid peroxidase autoantibodies in thyroid diseases. *J Clin Endocrinol Metab* 1990; 71, 661–669.
17. Huber G, Staub JJ, Meier C et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. *J Clin Endocrinol Metab* 2002; 87, 3221–3226.
18. Walsh JP, Bremner AP, Feddema P, Leedman PJ, Brown SJ, O'Leary P. Thyrotropin and thyroid antibodies as predictors of hypothyroidism: a 13-year, longitudinal study of a community-based cohort using current immunoassay techniques. *J Clin Endocrinol Metab* 2010; 95, 1095–1104.
19. Cooper DS, Biondi B. Subclinical thyroid disease. *Lancet* 2012; 379, 1142–1154.
20. Surks MI, Ortiz E, Daniels GH et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. *JAMA* 2004; 291, 228–238.
21. Biondi B. Cardiovascular effects of mild hypothyroidism. *Thyroid* 2007; 17, 625–630.
22. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. *Endocr Rev* 2008; 29, 76–131.
23. Owen PJ, Sabit R, Lazarus JH. Thyroid disease and vascular function. *Thyroid* 2007; 17, 519–524.
24. Gencer B, Collet TH, Virgini V et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. *Circulation* 2012; 126, 1040–1049.
25. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. *Ann Intern Med* 2000; 132, 270–278.
26. Nanchen D, Gusssekloo J, Westendorp RG et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. *J Clin Endocrinol Metab* 2012; 97, 852–861.

27. Rodondi N, den Elzen WP, Bauer DC et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. *JAMA* 2010; 304, 1365–1374.
28. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. *JAMA* 2004; 292, 2591–2599.
29. Hyland KA, Arnold AM, Lee JS, Cappola AR. Persistent subclinical hypothyroidism and cardiovascular risk in the elderly: the cardiovascular health study. *J Clin Endocrinol Metab* 2013; 98, 533–540.
30. Waring AC, Arnold AM, Newman AB, Buzkova P, Hirsch C, Cappola AR. Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study. *J Clin Endocrinol Metab* 2012; 97, 3944–3950.
31. Villar HC, Saconato H, Valente O, Atallah AN. Thyroid hormone replacement for subclinical hypothyroidism. *Cochrane Database Syst Rev* 2007; CD003419.
32. Meyerovitch J, Rotman-Pikielny P, Sherf M, Battat E, Levy Y, Surks MI. Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. *Arch Intern Med* 2007; 167, 1533–1538.
33. Stagnaro-Green A, Abalovich M, Alexander E et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. *Thyroid* 2011; 21, 1081–1125.
34. Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. *J Clin Endocrinol Metab* 2007; 92, 4575–4582.
35. Razvi S, Weaver JU, Butler TJ, Pearce SH. Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. *Arch Intern Med* 2012; 172, 811–817.
36. Persani L. Clinical review: Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. *J Clin Endocrinol Metab* 2012; 97, 3068–3078.
37. De Groot L, Abalovich M, Alexander EK et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2012; 97, 2543–2565.
38. Hennessey JV, Evaul JE, Tseng YC, Burman KD, Wartofsky L. L-thyroxine dosage: a reevaluation of therapy with contemporary preparations. *Ann Intern Med* 1986; 105, 11–15.
39. Gordon MB, Gordon MS. Variations in adequate levothyroxine replacement therapy in patients with different causes of hypothyroidism. *Endocr Pract* 1999; 5, 233–238.
<http://clinicaltrials.gov/ct2/show/NCT01660126>.
40. Spinas GA, Fischli S. *Endokrinologie und Stoffwechsel*. Thieme Verlag Stuttgart, 2011.
41. Surks MI, Sievert R. Drugs and thyroid function. *N Engl J Med* 1995; 333, 1688–1694.
42. <http://www.compendium.ch>.
- 43.